POZ July-August 2016
POZ July-August 2016
In every issue, you’ll find the hottest topics of interest to our readers along with cutting-edge health information.
Also Available On:
Features
The Re-invention Tour: Two of Madonna’s Blond Ambition dancers are long-term survivors shining the spotlight on HIV
Two of Madonna’s Blond Ambition dancers are long-term survivors now shining the spotlight on HIV.
Antiretrovirals: A Success Story—Celebrating 20 years of effective treatment
Celebrating 20 years of effective HIV treatment
The HIV Treatment Pipeline
“We need drugs that are gentler, kinder, better and cheaper.”
HIV by the Numbers
There are approximately 36.9 million people living with HIV worldwide
Facts and Fiction: A new novel by Tim Murphy explores the early years of the AIDS epidemic and imagines what lies in the future
A new novel explores the early years of the AIDS epidemic and imagines what lies in the future.
Milestones in the Era of Effective HIV Treatment
Here’s a timeline of the highlights.
2016 HIV Drug Chart
This quick-reference chart compares available medication options for HIV.
From the Editor
Rescue Me
I admit to being a longtime Madonna fan.
Feedback
Letters-July/August 2016
Feedback on the issue of gay men’s attraction to crystal meth and Bernie Sanders’s AIDS plan.
POZ Q+A
Positive Ends
The International AIDS Vaccine Initiative (IAVI) marks 20 years in the search for an end to the epidemic.
POZ Planet
Heroes Tour 2016
Doug Meyer makes sculptures of creative icons lost to AIDS.
Be a Quitter
This free online program helps HIV-positive smokers kick the habit.
Palm Springs HIV Profiles
The documentary Desert Migration spotlights 13 long-term survivors, all men, now living in Palm Springs, California.
Painting the Epidemic
The painter Hugh Steers died of AIDS-related illness at age 32 in 1995, a time when figurative painting like his was not in vogue.
Voices
My Sanctuary
Daniel Szymczyk, founder and CEO of The HIV League, shares why he started the nonprofit group and how running became a passion.
POZ Survey Says
Trial and Error
POZ recently asked whether you’ve ever participated in a clinical trial or would consider it. Here are your responses.
Research Notes
Prevention: Prison Proposal
Sending fewer men to prison and reducing sentences for those who are incarcerated could slow the spread of HIV.
Treatment: Hep C Horizons
Gilead Sciences’ HCV combo tablet regimen of Sovaldi and velpatasvir can be combined safely with most “boosted” antiretroviral treatment...
Cure: Suppressed Monkeys
An HIV cure drug from Gilead Sciences, GS-9620, has shown promise in rhesus macaque monkeys.
Concerns: Resistant Strains
People contracting HIV are increasingly acquiring strains that are resistant to antiretrovirals (ARVs).
Care and Treatment
A Much Healthier HIV Epidemic?
A new study suggests the HIV epidemic is actually in much better shape.
Media Jumps the HIV Cure Gun Yet Again
A slew of media outlets erroneously reported that scientists might be just three years away from developing a cure for HIV.
FDA OKs Gilead’s Descovy (Not for PrEP)
The U.S. Food and Drug Administration approved Gilead Sciences’ Descovy for the treatment of HIV in combination with other antiretrovirals.
Starting HIV Treatment May Improve Liver Health
Beginning antiretroviral treatment for HIV may provide a boost to liver health among those with and without hepatitis B or C viruses.
Early HIV Treatment Ups Quality of Life
Starting HIV treatment soon after diagnosis leads to modest improvements in quality of life compared with delaying treatment.
POZ Heroes
Together We Fight
Gregg Gonsalves first became involved in AIDS activism in the late 1980s, working with ACT UP Boston before moving to New York City.
